SURVANTA CAN RAPIDLY AFFECT OXYGENATION AND LUNG COMPLIANCE. During controlled clinical trials, the most commonly reported adverse experiences were associated with the dosing procedure and involved transient bradycardia 11.9% of doses; oxygen desaturation 9.8% of doses and endotracheal tube reflux, fewer than 1% of doses.

* IMS DDD Lung Surfactant Market Purchases July 1991 through June 2007. On file, Abbott Nutrition Marketing Research.

Over 750,000 infants treated since 1991*

Please see Prescribing Information Tab for Full Prescribing Information.